Cefotaxime Monograph - Paediatric

**Scope (Staff):** Medical, Pharmacy, Nursing

**Scope (Area):** All Clinical Areas

**Child Safe Organisation Statement of Commitment**

CAHS commits to being a child safe organisation by applying the National Principles for Child Safe Organisations. This is a commitment to a strong culture supported by robust policies and procedures to reduce the likelihood of harm to children and young people.

This document should be read in conjunction with this **DISCLAIMER**

**QUICKLINKS**

<table>
<thead>
<tr>
<th>Dosage/Dosage Adjustments</th>
<th>Administration</th>
<th>Compatibility</th>
<th>Monitoring</th>
</tr>
</thead>
</table>

**DRUG CLASS**

Broad spectrum cephalosporin,\(^{(1, 2)}\)

**INDICATIONS AND RESTRICTIONS**

- Cefotaxime is active against the majority of enteric Gram-negative bacilli, *Streptococcus pneumoniae* and has dose dependent activity against methicillin susceptible *Staphylococcus aureus* (MSSA). It has good CNS penetration.\(^{(2)}\)
- Ceftriaxone is preferred to cefotaxime in all patients except neonates.

**Oral: Monitored (orange) antibiotic**

- If the use is consistent with a standard approved indication, this must be communicated to ChAMP by documenting that indication on all prescriptions (inpatient and outpatient).
- The ChAMP team will review if ongoing therapy is required and/or if the order does not meet ChAMP Standard Indications
- If use is not for a standard approved indication, phone approval must be obtained from ChAMP before prescribing.
CONTRAINDICATIONS

- Hypersensitivity to cefotaxime, any component of the formulation or patients with a history of high risk allergy to cephalosporins.\(^{(1, 3-7)}\)

PRECAUTIONS

- Cefotaxime may be prescribed in selected patients with high risk allergy to another Beta-lactam sub-class (e.g. some penicillins, carbapenems) in discussions with immunology.\(^{(1)}\)
- In patients with a previous low risk reaction to cefotaxime or another cephalosporin (delayed rash [>1hr after initial exposure] without mucosal or systemic involvement) the risk of subsequent reaction is low. Re-challenge may be acceptable in discussion with immunology
- Rapid IV injection has resulted in life-threatening cardiac arrhythmias; ensure IV injections are given over a minimum of 3 to 5 minutes.\(^{(1, 3, 8)}\)
- Each gram of cefotaxime contains 48 mg (2.1 mmol) of sodium.\(^{(1, 3, 6)}\)

FORMULATIONS

Listed below are products available at PCH, other formulations may be available, check with pharmacy if required:

- 1 gram powder for injection vial

Imprest location: Formulary One

DOSAGE & DOSAGE ADJUSTMENTS

**Neonates:** Refer to Neonatal Medication Protocols

**IV (Children ≥ 4 weeks):**

- **Usual dose:** 50 mg/kg/dose (to a maximum of 2 grams) 8 hourly.\(^{(1, 9)}\)
- **Severe infections (e.g. meningitis):** 50 mg/kg/dose (to a maximum of 2 grams) 6 hourly.\(^{(1, 9)}\)

Dosing in Overweight and Obese Children: Dose based on measured body weight.\(^{(10)}\)

Renal impairment:

eGFR calculator

- eGFR: ≥ 20 to 50 mL/minute: 100% dose given 8 to 12hourly
- eGFR: < 20 mL/minute: 50% dose given 8 to 12 hourly.\(^{(2)}\)

Hepatic impairment:

- No dosage adjustments are required for hepatic impairment.\(^{(5, 7)}\)
**RECONSTITUTION & ADMINISTRATION**

**Reconstitution:**
- Reconstitute each 1 gram vial with the volume of water for injection in the table below. Further dilution with a compatible fluid to a concentration of 40 mg/mL is required prior to IV infusion.\(^\text{(3, 11)}\)

<table>
<thead>
<tr>
<th>Vial strength</th>
<th>Volume of water for injection required</th>
<th>Resulting concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 gram</td>
<td>9.6 mL (powder volume 0.4 mL)</td>
<td>100 mg/mL</td>
</tr>
</tbody>
</table>

**Administration**

**IV injection:**
- Dilute to a final concentration of 100 mg/mL or weaker and give by slow IV injection over 3 to 5 minutes.\(^\text{(3, 7)}\)
- **Note:** life threatening arrhythmias have occurred with rapid IV injection (when administered over 1 minute). Ensure IV injections are given over 3 to 5 minutes.\(^\text{(1, 3, 7)}\)

**IV infusion:**
- Dilute to a final concentration of 40 mg/mL or weaker with compatible fluid and infuse over 20 to 30 minutes.\(^\text{(3, 7)}\)

**COMPATIBILITY (LIST IS NOT EXHAUSTIVE)**

**Compatible fluids:**
- Glucose 5% and 10%
- Sodium chloride 0.9%
- Glucose / sodium chloride solutions
- Hartmann’s.\(^\text{(3)}\)

**Compatible at Y-site:**
*Compatibilities of IV drugs* must be checked when two or more drugs are given concurrently.

**MONITORING**

- Renal, hepatic and haematological function should be monitored weekly with prolonged therapy (i.e. longer than 7 days).\(^\text{(1, 5, 7)}\)

**ADVERSE EFFECTS**

**Common:** diarrhoea, nausea, abdominal pain, vomiting, pain and inflammation at injection site, rash, headache, dizziness, allergy, *Clostridioides difficile*-associated disease.\(^\text{(1, 4)}\)
Infrequent: anaphylaxis, angioedema

Rare: life-threatening arrhythmias with rapid IV administration, neurotoxicity (e.g., confusion, seizures, encephalopathy) especially with high doses and/or renal impairment, blood dyscrasias (e.g., neutropenia), thrombocytopenia, bleeding, renal impairment, immunologic reactions.

STORAGE

• Store vials below 25˚C and protect from light.
• Store syringes prepared by Pharmacy Compounding Service (PCS) between 2 -8˚C and protect from light.

INTERACTIONS

This medication may interact with other medications; consult PCH approved references (e.g. Clinical Pharmacology), a clinical pharmacist or PCH Medicines Information Service on extension 63546 for more information.

**Please note: The information contained in this guideline is to assist with the preparation and administration of cefotaxime. Any variations to the doses recommended should be clarified with the prescriber prior to administration.**

Related CAHS internal policies, procedures and guidelines

- Antimicrobial Stewardship Policy
- ChAMP Empirc Guidelines and Monographs
- KEMH Neonatal Medication Protocols

References

7. Paediatric Drug information [Internet]. Lexicomp. 2022 [cited 23/08/2022].
9. Royal Australian College of General Practitioners, Pharmaceutical Society of Australia, Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. AMH:
Cefotaxime Monograph - Paediatrics


This document can be made available in alternative formats on request for a person with a disability.

<table>
<thead>
<tr>
<th>File Path:</th>
<th>W:\Paediatrics\PMH\ChAMP\Monographs\FINALISED\00 Current version 00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Document Owner:</td>
<td>Head of Department – Infectious Diseases</td>
</tr>
<tr>
<td>Reviewer / Team:</td>
<td>Children's Antimicrobial Management Program Pharmacist</td>
</tr>
<tr>
<td>Date First Issued:</td>
<td>September 2013</td>
</tr>
<tr>
<td>Amendment Dates:</td>
<td>October 2019, June 2020, October 2022</td>
</tr>
<tr>
<td>Approved by:</td>
<td>Drugs and Therapeutics Committee</td>
</tr>
<tr>
<td>Endorsed by:</td>
<td>Chair, Drugs and Therapeutics Committee</td>
</tr>
<tr>
<td>Standards Applicable:</td>
<td>NSQHS Standards: [ ] [ ] [ ]</td>
</tr>
<tr>
<td></td>
<td>Child Safe Standards: N/A</td>
</tr>
</tbody>
</table>

Printed or personally saved electronic copies of this document are considered uncontrolled.

Healthy kids, healthy communities

[Compassion] [Excellence] [Collaboration] [Accountability] [Equity] [Respect]

Neonatology | Community Health | Mental Health | Perth Children’s Hospital